Page 27 - Pharma Sector

Utkarsh Small Finance Bank proposes reverse merger with holding entity

The bank has said it has taken note of the proposal and the Board of Directors of the lender will meet in due course and evaluate the proposal and other options to achieve regulatory compliance

Gland Pharma Q3 results: Net porfit at Rs 192 cr, revenue at Rs 1,545 cr

Gland Pharma on Wednesday said its consolidated Profit After Tax (PAT) stood at Rs 192 crore for the December quarter. The drug firm had reported a PAT of Rs 232 crore in the year-ago period. The company's revenue from operations stood at Rs 1,545 crore for the October-December period, up from Rs 938 a year ago. The results for the quarter under review and the nine months of the current fiscal are not comparable to the earlier periods of the previous year due to the inclusion of Cenexi results, the Hyderabad-based company said. On November 29, 2022, the Hyderabad-based drug Contract Development and Manufacturing Company (CDMO) had entered into a put option agreement to acquire Cenexi Group for up to 120 million euros, marking its foray into the international markets. "In the ex-Cenexi base business, we are happy to keep up with the growth aspirations, and the performance has been encouraging with the introduction of new products and improved volumes of the current basket," Gland .

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Eris Lifesciences Q3 results: Profit flat at Rs 102 crore, revenue up 16%

On a sequential basis, the company saw a 3.40 per cent decline in revenue along with Profit After Tax (PAT), which also declined by 16.77 per cent

Dr Reddy's Laboratories R&D facility gets VAI status in USFDA inspection

Last year in December, during the Good Manufacturing Practice (GMP) and Pre-Approval Inspection at the same facility concluded with three observations

Aurobindo Pharma Q3 results: Profit up 91.43%, revenue rises 14.7%

The company's revenue from formulations increased by 17.2 per cent Y-o-Y to Rs 6,291 crore. Sequentially, it was up by 5.4 per cent from Rs 5,968 crore in Q2 FY24

Zydus Lifesciences Q3FY24 results: Profit up 27% at Rs 790 crore

Zydus Lifesciences on Friday said its consolidated net profit increased by 27 per cent to Rs 790 crore in the third quarter ended December 31, 2023. The drugmaker had reported a net profit of Rs 623 crore in the October-December period a year ago. Revenue increased to Rs 4,505 crore in the third quarter from Rs 4,257 crore in the year-ago period, Zydus Lifesciences said in a statement. The company said its board has approved a proposal to buy back shares of up to Rs 600 crore. "We are pleased with our Q3 FY24 performance, particularly with a strong recovery in the domestic formulations business and a resilient US base business," Zydus Lifesciences Managing Director Sharvil Patel said. He further said: "We are optimistic about our growth prospects driven by a differentiated portfolio in the US, continued performance of key brands, well supported by a robust execution engine." The company remains on track to end the fiscal year 2024 with a healthy double-digit revenue growth, Patel

Promoters of Mankind Pharma divest 1.6% stake worth Rs 1,367 crore

Mankind Pharma promoters on Thursday divested a 1.62 per cent stake in the company for Rs 1,367 crore through open market transactions. According to the block deal data available with the NSE, promoters Sheetal Arora, Puja Juneja, and Arjun Juneja offloaded a total of 64,89,534 shares in two tranches each, representing a 1.62 per cent stake in Mankind Pharma, on the NSE. The shares were disposed of at an average price of Rs 2,107.35 apiece, taking the combined deal value to Rs 1,367.57 crore. Through the latest transaction, the combined shareholding of promoter and promoter group entities have declined to 74.88 per cent stake from 76.50 per cent stakeholding (as of December quarter) in Mankind Pharma. As per market regulations, all listed companies must maintain an minimum public shareholding of 25 per cent, while newly-listed firms are given three years to meet the requirement of 25 per cent public float. Accordingly, after the stake sale, the company has complied with the norms

Biocon Q3FY24 results: Net profit at Rs 660 crore, revenue up 50%

Biocon's overall growth was boosted by the conclusion of the transition of the acquired business by Biocon Biologics and pre-payment of $200 million towards the acquisition-related debt reduction

Health tech startup Neodocs raises Rs 16.6 cr in seed funding round

Company that makes smartphone-based medical test kits will use the financing to expand business

P&G Health Q2 results: Net profit dips 6% to Rs 72 cr, income at Rs 315 cr

Procter & Gamble Health Ltd on Tuesday said its profit after tax declined 6 per cent to Rs 72 crore for the second quarter ended December 2023. The company had reported a Profit After Tax (PAT) of Rs 77 crore in the October-December period of the last fiscal. Total income for the period under review stood at Rs 315 crore as against Rs 314 crore in the year-ago period, Procter & Gamble Health said in a regulatory filing. The company follows a July-June financial year. "This has been a challenging quarter for the company on account of an overall slowdown in the vitamins, minerals and supplements category coupled with a delayed seasonal onset," P&G Health India MD Milind Thatte said. With improved productivity, efficiency and continued strategic investments, the company has been able to deliver a modest topline and bottomline, he added. The company said its board has declared an interim dividend of Rs 200 per share for the financial year 2023-24. Shares of the company settled

Indian pharma industry relies heavily on ingredients made in China: Report

America's reliance on China for drug ingredients has raised alarm bells in Congress. House committees will hold two hearings Tuesday on drug shortages

Alembic Pharma Q3 results: Profit up 48% as raw material cost declines

This increase in PAT was attributed to tax deduction, decline in the cost of materials consumed, and improvement in Ebitda

Abbott Q3 results: Profit rises 26% to Rs 311 cr on strong demand

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier

Mankind Pharma Q3 results: PAT up 55% on strong domestic performance

Mankind's revenue from operations rose to Rs 2,607 crore in Q3 FY24, a 25 per cent Y-o-Y rise in revenue from operations from Rs 2,128 crore in Q2 FY23

Pfizer posts surprise 4th quarter profit, but key products miss on sales

The New York-based drugmaker earned 10 cents per share on an adjusted basis for the fourth quarter. Analysts on average had expected a loss of 22 cents per share, according to LSEG data

Dr Reddy's Lab Q3 results: PAT up 11%, beats estimates on strong US sales

The Hyderabad-based drug major had reported a net profit of Rs 1,247 crore for the October-December quarter of the last fiscal

Launch delays key risk to outlook for pharma company Cipla stock

The company reported a 13.7 per cent increase in sales to Rs 6,603 crore led by 11.5 per cent growth in the India business

SSWC&MA approves Rs 1,937 cr project proposals for industrial expansion

The State Single Window Clearance & Monitoring Authority (SSWC&MA) has approved 27 project proposals for setting up new industrial enterprises and undertaking substantial expansion of existing units with proposed investment of around Rs 1,937 crore. SSWC&MA has approved Rs 1,937 crore project proposals and employment opportunities for 2,715 people, according to a press statement issued here on Saturday. The decision was taken during the 28th meeting of the SSWC&MA, which was presided over by Chief Minister Sukhwinder Singh Sukhu. The new proposals approved by the Authority include proposals of Xenone Healthcare and Master Formulations CO for manufacturing of tablets, capsules and ointments. Some of the other approved proposals include that of Gowthami Aquachem for manufacturing of Sodium Chlorite, Him Deep Alkalies Chemical for manufacturing of Caustic Soda Liquid, Hydrogen and Chlorine, Agro Farm Ventures for setting up a cold store, Scottill Healthcare for ...